Sulindac is a non-steroidal anti-inflammatory drug of the arylalkanoic acid class that is marketed in the U.S. by Merck as Clinoril.
Like other NSAIDs, it is useful in the treatment of acute or chronic inflammatory conditions.
Its usual dosage is 150-200 milligrams twice per day, with food. It should not be used by persons with major allergic reactions (urticaria or anaphylaxis) to aspirin or other NSAIDs, and should be used with caution by persons having pre-existing peptic ulcer disease. Sulindac is much more likely than other NSAIDs to cause damage to the liver or pancreas.
Sulindac seems to have a property, independent of COX-inhibition, in reducing the growth of polyps and precancerous lesions in the colon, especially in association with familial adenomatous polyposis.
Sulindac is an effective tocolytic and may be used in the treatment of preterm labour.
In common with other NSAIDs, sulindac is currently being investigated for its role in the treatment of Alzheimer's disease.
2007-02-10 00:35:30
·
answer #1
·
answered by davoodnjn 1
·
0⤊
0⤋